

January 13, 2026

Company Name: CellSeed Inc. (TSE 7776)

Representative: Setsuko Hashimoto, Ph.D. President and CEO

Contact: Keiichiro Nakaoka Director, Corporate Management

Telephone: +81 3-6380-7490

## **CellSeed Enters Agreement with Cuorips Inc. for Cell Cultureware**

Tokyo, Japan - CellSeed Inc. (hereinafter “the Company”) hereby announces that it has entered into a Basic Sales and Purchase Agreement with Cuorips Inc. (Head Office: 3-11-5 Nihonbashi-Honcho, Chuo-ku, Tokyo; President & CEO: Takayuki Kusanagi; hereinafter “Cuorips”) on January 6, 2026, regarding the supply of cell cultureware, as outlined below.

### **1. Purpose and Details of the Agreement**

The Company has executed a Basic Sales and Purchase Agreement with Cuorips with the aim of ensuring a stable supply of our temperature-responsive cell cultureware product, UpCell® ADVANCE, which will be used in the manufacturing process of the human (allogeneic) iPS cell-derived cardiomyocyte sheet developed by Cuorips.

Cuorips submitted a marketing authorization application for this regenerative medical product—targeting to treat severe heart failure caused by ischemic cardiomyopathy—to the Ministry of Health, Labour and Welfare in April 2025.

### **2. Profile of Cuorips Inc.**

Company Name: Cuorips Inc.

Location: Nihonbashi Life Science Building 2, 3-11-5 Nihonbashi-Honcho, Chuo-ku, Tokyo

Representative: Takayuki Kusanagi, President & CEO

Principal Business: Development and commercialization of human iPS cell-derived cardiomyocyte sheets

Date of Establishment: March 21, 2017